Heart rate variability and cardiac diseases

Eiichi Watanabe, Ken Kiyono, Yoshiharu Yamamoto, Junichiro Hayano

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Heart rate variability (HRV) is a noninvasive methodology for evaluating the autonomic nervous system modulation of the sinoatrial node and to identify patients at risk of cardiac disorders. The contemporary therapeutic use for the HRV analysis is for risk stratification in patients with post-myocardial infarction or heart failure who are prone to have arrhythmic death and who would benefit from implantable cardioverter-defibrillators (ICDs). Although multiple HRV measurements have been developed to achieve a better risk stratification, the HRV measurements have been rarely tested to see whether they harbor a significant power to serve as a practical risk predictor. To date, the only reliable metric to predict the benefit from an ICD is a severely reduced ejection fraction; however, the predictive value of the ejection fraction is relatively low. Because of the high negative predictive value of the HRV, a combination with the ejection fraction may be helpful to identify candidates who are unlikely to benefit from ICD therapy. A more sophisticated risk approach that combines the HRV and other known clinical measures should be developed to provide accurate estimates of the risk to allow patients to make informed treatment decisions. Another requirement is to explore the novel HRV measurements for atrial fibrillation. The prevalence of atrial fibrillation rapidly increases among the aging population and is independently associated with a higher risk of ischemic strokes and excess mortality. The HRV measurements specific for atrial fibrillation may facilitate the risk stratification in such a high-risk population.

Original languageEnglish
Title of host publicationClinical Assessment of the Autonomic Nervous System
PublisherSpringer Japan
Pages163-178
Number of pages16
ISBN (Electronic)9784431560128
ISBN (Print)9784431560104
DOIs
Publication statusPublished - 01-01-2016

Fingerprint

Heart Diseases
Heart Rate
Implantable Defibrillators
Atrial Fibrillation
Heart Failure
Sinoatrial Node
Autonomic Nervous System
Therapeutic Uses
Population
Stroke
Myocardial Infarction
Mortality
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Neuroscience(all)

Cite this

Watanabe, E., Kiyono, K., Yamamoto, Y., & Hayano, J. (2016). Heart rate variability and cardiac diseases. In Clinical Assessment of the Autonomic Nervous System (pp. 163-178). Springer Japan. https://doi.org/10.1007/978-4-431-56012-8_10
Watanabe, Eiichi ; Kiyono, Ken ; Yamamoto, Yoshiharu ; Hayano, Junichiro. / Heart rate variability and cardiac diseases. Clinical Assessment of the Autonomic Nervous System. Springer Japan, 2016. pp. 163-178
@inbook{f49bf6f9c57e4918ba4df59ba89575cc,
title = "Heart rate variability and cardiac diseases",
abstract = "Heart rate variability (HRV) is a noninvasive methodology for evaluating the autonomic nervous system modulation of the sinoatrial node and to identify patients at risk of cardiac disorders. The contemporary therapeutic use for the HRV analysis is for risk stratification in patients with post-myocardial infarction or heart failure who are prone to have arrhythmic death and who would benefit from implantable cardioverter-defibrillators (ICDs). Although multiple HRV measurements have been developed to achieve a better risk stratification, the HRV measurements have been rarely tested to see whether they harbor a significant power to serve as a practical risk predictor. To date, the only reliable metric to predict the benefit from an ICD is a severely reduced ejection fraction; however, the predictive value of the ejection fraction is relatively low. Because of the high negative predictive value of the HRV, a combination with the ejection fraction may be helpful to identify candidates who are unlikely to benefit from ICD therapy. A more sophisticated risk approach that combines the HRV and other known clinical measures should be developed to provide accurate estimates of the risk to allow patients to make informed treatment decisions. Another requirement is to explore the novel HRV measurements for atrial fibrillation. The prevalence of atrial fibrillation rapidly increases among the aging population and is independently associated with a higher risk of ischemic strokes and excess mortality. The HRV measurements specific for atrial fibrillation may facilitate the risk stratification in such a high-risk population.",
author = "Eiichi Watanabe and Ken Kiyono and Yoshiharu Yamamoto and Junichiro Hayano",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-4-431-56012-8_10",
language = "English",
isbn = "9784431560104",
pages = "163--178",
booktitle = "Clinical Assessment of the Autonomic Nervous System",
publisher = "Springer Japan",
address = "Japan",

}

Watanabe, E, Kiyono, K, Yamamoto, Y & Hayano, J 2016, Heart rate variability and cardiac diseases. in Clinical Assessment of the Autonomic Nervous System. Springer Japan, pp. 163-178. https://doi.org/10.1007/978-4-431-56012-8_10

Heart rate variability and cardiac diseases. / Watanabe, Eiichi; Kiyono, Ken; Yamamoto, Yoshiharu; Hayano, Junichiro.

Clinical Assessment of the Autonomic Nervous System. Springer Japan, 2016. p. 163-178.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Heart rate variability and cardiac diseases

AU - Watanabe, Eiichi

AU - Kiyono, Ken

AU - Yamamoto, Yoshiharu

AU - Hayano, Junichiro

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Heart rate variability (HRV) is a noninvasive methodology for evaluating the autonomic nervous system modulation of the sinoatrial node and to identify patients at risk of cardiac disorders. The contemporary therapeutic use for the HRV analysis is for risk stratification in patients with post-myocardial infarction or heart failure who are prone to have arrhythmic death and who would benefit from implantable cardioverter-defibrillators (ICDs). Although multiple HRV measurements have been developed to achieve a better risk stratification, the HRV measurements have been rarely tested to see whether they harbor a significant power to serve as a practical risk predictor. To date, the only reliable metric to predict the benefit from an ICD is a severely reduced ejection fraction; however, the predictive value of the ejection fraction is relatively low. Because of the high negative predictive value of the HRV, a combination with the ejection fraction may be helpful to identify candidates who are unlikely to benefit from ICD therapy. A more sophisticated risk approach that combines the HRV and other known clinical measures should be developed to provide accurate estimates of the risk to allow patients to make informed treatment decisions. Another requirement is to explore the novel HRV measurements for atrial fibrillation. The prevalence of atrial fibrillation rapidly increases among the aging population and is independently associated with a higher risk of ischemic strokes and excess mortality. The HRV measurements specific for atrial fibrillation may facilitate the risk stratification in such a high-risk population.

AB - Heart rate variability (HRV) is a noninvasive methodology for evaluating the autonomic nervous system modulation of the sinoatrial node and to identify patients at risk of cardiac disorders. The contemporary therapeutic use for the HRV analysis is for risk stratification in patients with post-myocardial infarction or heart failure who are prone to have arrhythmic death and who would benefit from implantable cardioverter-defibrillators (ICDs). Although multiple HRV measurements have been developed to achieve a better risk stratification, the HRV measurements have been rarely tested to see whether they harbor a significant power to serve as a practical risk predictor. To date, the only reliable metric to predict the benefit from an ICD is a severely reduced ejection fraction; however, the predictive value of the ejection fraction is relatively low. Because of the high negative predictive value of the HRV, a combination with the ejection fraction may be helpful to identify candidates who are unlikely to benefit from ICD therapy. A more sophisticated risk approach that combines the HRV and other known clinical measures should be developed to provide accurate estimates of the risk to allow patients to make informed treatment decisions. Another requirement is to explore the novel HRV measurements for atrial fibrillation. The prevalence of atrial fibrillation rapidly increases among the aging population and is independently associated with a higher risk of ischemic strokes and excess mortality. The HRV measurements specific for atrial fibrillation may facilitate the risk stratification in such a high-risk population.

UR - http://www.scopus.com/inward/record.url?scp=85006386987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006386987&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-56012-8_10

DO - 10.1007/978-4-431-56012-8_10

M3 - Chapter

AN - SCOPUS:85006386987

SN - 9784431560104

SP - 163

EP - 178

BT - Clinical Assessment of the Autonomic Nervous System

PB - Springer Japan

ER -

Watanabe E, Kiyono K, Yamamoto Y, Hayano J. Heart rate variability and cardiac diseases. In Clinical Assessment of the Autonomic Nervous System. Springer Japan. 2016. p. 163-178 https://doi.org/10.1007/978-4-431-56012-8_10